Importance of Testing

Sensitizing EGFR mutations are common in newly diagnosed patients with mNSCLC1,2


EGFR mutation prevalence at diagnosis1,2

EGFR mutation prevalence at diagnosis of metastatic non-small cell lung cancer (NSCLC)
EGFR mutation prevalence at diagnosis of metastatic non-small cell lung cancer (NSCLC)

The prevalence of sensitizing EGFR mutations varies by ethnicity: 7% to 23% in Western patients vs 30% to 50% in Asian patients.3-6

Sensitizing EGFR mutations are predictive of response to first-line EGFR-TKIs

Response icon
Response icon

Patients with EGFRm mNSCLC treated with first-line EGFR-TKIs in clinical trials had7-12:

  • Longer progression-free survival
  • Higher overall response rates

According to ASCO and NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), newly diagnosed patients with mNSCLC should be tested for sensitizing EGFR mutations and, if positive, treated with an EGFR-TKI13-15,*

ASCO, American Society of Clinical Oncology; EGFR, epidermal growth factor receptor; EGFRm, EGFR mutation–positive; mNSCLC, metastatic non–small cell lung cancer; NCCN, National Comprehensive Cancer Network; TKI, tyrosine kinase inhibitor.

*The NCCN Guidelines® for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques but do not endorse any specific commercially available biomarker assays.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

References: 1. Sholl LM et al. J Thorac Oncol. 2015;10(5):768-777. 2. Sharma SV et al. Nat Rev Cancer. 2007;7(3):169-181. 3. Shi Y et al. J Thorac Oncol. 2014;9(2):154-162. 4. Sekine I et al. Br J Cancer. 2008;99(11):1757-1762. 5. Shigematsu H et al. J Natl Cancer Inst. 2005;97(5):339-346. 6. D'Angelo SP et al. J Clin Oncol. 2011;29(15):2066-2070. 7. Wu YL et al. Lancet Oncol. 2014;15(2):213-222. 8. Rosell R et al. Lancet Oncol. 2012;13(3):239-246. 9. Mitsudomi T et al. Lancet Oncol. 2010;11(2):121-128. 10. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334. 11. Zhou C et al. Lancet Oncol. 2011;12(8):735-742. 12. Soria JC et al. N Engl J Med. 2018;378(2):113-125. 13. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V2.2021. © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. Accessed December 23, 2020. To view the most recent and complete version of the guidelines, go online to 14. Hanna N et al. J Clin Oncol. 2017;35(30):3484-3515. 15. Leighl NB et al. J Clin Oncol. 2014;32(32):3673-3679.